Chutong Lin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Chutong Lin has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Shanwu Ma
Department of Thoracic Surgery Peking University Third Hospital Beijing China
4 shared publications - Guangliang Qiang
Department of Thoracic Surgery Peking University Third Hospital Beijing China
3 shared publications - Huayu He
Department of Thoracic Surgery Peking University Third Hospital Beijing China
2 shared publications - Jizheng Tang
Department of Thoracic Surgery Peking University Third Hospital Beijing China
2 shared publications - Fengling Hu
Department of Thoracic Surgery Peking University Third Hospital Beijing China
1 shared publication Fuxin Guo
Department of Radiation Oncology Peking University Third Hospital Beijing China
1 shared publication
Latest Publications
- Open Access
- 13 November 2026
- Published by Wiley in IUBMB Life
- Vol. 78 (11)
ACOT11 Couples Lipid Hydrolysis to GPR40‐Associated Metabolic Rewiring and Neutrophil–PD‐L1‐Associated Immunomodulation in Non‐Small Cell Lung Cancer
Chemoresistance in non‐small cell lung cancer (NSCLC) is frequently accompanied by metabolic reprogramming and immune evasion. ACOT11 (THEM1/STARD14) is an acyl‐CoA thioesterase that can tune intracellular free fatty acid (FFA) availability, but the downstream signaling and microenvironmental consequences relevant to resistance remain incompletely defined. ACOT11 expression and prognostic associations were analyzed in TCGA LUAD datasets (DESeq2) and Kaplan–Meier Plotter. ACOT11 levels were validated in paired patient tumor/adjacent tissues ( n = 30) by RT–qPCR and immunohistochemistry. Gain‐ and loss‐of‐function studies were performed in A549 and NCI‐H1975 cells. FFAs were quantified colorimetrically/fluorometrically, while proliferation, clonogenicity, and motility were assessed using CCK‐8, colony formation, and Transwell assays. Bioenergetic profiling was performed by Seahorse OCR/ECAR measurements, complemented by ATP and lactate quantification. Neutrophils and CD8 + T cells were isolated from PBMCs for co‐culture assays with PD‐L1 blockade, and PD‐L1 was quantified by flow cytometry and immunoblotting. Tumor growth effects were evaluated in nude mouse xenografts with ACOT11 silencing and neutrophil supplementation. ACOT11 was dysregulated in LUAD and associated with worse survival, and was elevated in clinical tumors at mRNA and protein levels. In NSCLC cells, ACOT11 increased FFA abundance and selectively changes in GPR40 but not GPR120. Exogenous FFA partially rescued the proliferative and migratory defects induced by ACOT11 knockdown, and this rescue was blunted by GPR40 co‐silencing. ACOT11 depletion reduced OCR/ECAR, ATP, and lactate output, consistent with impaired energetic capacity, whereas FFA restored these parameters in a GPR40‐dependent manner, suggesting that this pathway likely contributes to the observed metabolic effects. ACOT11 aligned with neutrophil‐associated inflammatory signatures and increased MPO staining in tumors; ACOT11 loss reduced SPP1/CXCL2 expression, reversible by FFA–GPR40 signaling. Functionally, neutrophils were observed to restore PD‐L1 levels and suppress T‐cell effector outputs in co‐culture settings, and neutrophil supplementation partially rescued xenograft growth; PD‐L1 blockade enhanced T‐cell cytokine/perforin production and migration. Collectively, these findings support a working model in which ACOT11‐associated lipid signaling may contribute to an immunosuppressive milieu involving neutrophils and PD‐L1. ACOT11 is associated with increased FFA availability and engagement of a GPR40‐linked metabolic program, alongside neutrophil–PD‐L1‐associated immunosuppression, which may collectively contribute to NSCLC fitness. Targeting components of the ACOT11‐FFA‐GPR40 pathway, alone or combined with PD‐L1 blockade, may represent a mechanistically grounded strategy to weaken tumor bioenergetic reserve and immune escape in NSCLC.
- 13 November 2026
- Published by Wiley in IUBMB Life
- Vol. 78 (11)
Open AccessACOT11 Couples Lipid Hydrolysis to GPR40‐Associated Metabolic Rewiring and Neutrophil–PD‐L1‐Associated Immunomodulation in Non‐Small Cell Lung Cancer
Chemoresistance in non‐small cell lung cancer (NSCLC) is frequently accompanied by metabolic reprogramming and immune evasion. ACOT11 (THEM1/STARD14) is an acyl‐CoA thioesterase that can tune intracellular free fatty acid (FFA) availability, but the downstream signaling and microenvironmental consequences relevant to resistance remain incompletely defined. ACOT11 expression and prognostic associations were analyzed in TCGA LUAD datasets (DESeq2) and Kaplan–Meier Plotter. ACOT11 levels were validated in paired patient tumor/adjacent tissues ( n = 30) by RT–qPCR and immunohistochemistry. Gain‐ and loss‐of‐function studies were performed in A549 and NCI‐H1975 cells. FFAs were quantified colorimetrically/fluorometrically, while proliferation, clonogenicity, and motility were assessed using CCK‐8, colony formation, and Transwell assays. Bioenergetic profiling was performed by Seahorse OCR/ECAR measurements, complemented by ATP and lactate quantification. Neutrophils and CD8 + T cells were isolated from PBMCs for co‐culture assays with PD‐L1 blockade, and PD‐L1 was quantified by flow cytometry and immunoblotting. Tumor growth effects were evaluated in nude mouse xenografts with ACOT11 silencing and neutrophil supplementation. ACOT11 was dysregulated in LUAD and associated with worse survival, and was elevated in clinical tumors at mRNA and protein levels. In NSCLC cells, ACOT11 increased FFA abundance and selectively changes in GPR40 but not GPR120. Exogenous FFA partially rescued the proliferative and migratory defects induced by ACOT11 knockdown, and this rescue was blunted by GPR40 co‐silencing. ACOT11 depletion reduced OCR/ECAR, ATP, and lactate output, consistent with impaired energetic capacity, whereas FFA restored these parameters in a GPR40‐dependent manner, suggesting that this pathway likely contributes to the observed metabolic effects. ACOT11 aligned with neutrophil‐associated inflammatory signatures and increased MPO staining in tumors; ACOT11 loss reduced SPP1/CXCL2 expression, reversible by FFA–GPR40 signaling. Functionally, neutrophils were observed to restore PD‐L1 levels and suppress T‐cell effector outputs in co‐culture settings, and neutrophil supplementation partially rescued xenograft growth; PD‐L1 blockade enhanced T‐cell cytokine/perforin production and migration. Collectively, these findings support a working model in which ACOT11‐associated lipid signaling may contribute to an immunosuppressive milieu involving neutrophils and PD‐L1. ACOT11 is associated with increased FFA availability and engagement of a GPR40‐linked metabolic program, alongside neutrophil–PD‐L1‐associated immunosuppression, which may collectively contribute to NSCLC fitness. Targeting components of the ACOT11‐FFA‐GPR40 pathway, alone or combined with PD‐L1 blockade, may represent a mechanistically grounded strategy to weaken tumor bioenergetic reserve and immune escape in NSCLC.
- Open Access
- 7 April 2026
- Published by Wiley in Thoracic Cancer
- Vol. 17 (7) , e70270
Optimizing Surgery Strategies in Stage IB Lung Squamous Cell Carcinoma: Insights from Interpretable Machine Learning
Background: Stage IB lung squamous‐cell carcinoma (LSCC) lacks individualized survival prediction tools. There's debate on adjuvant chemotherapy's benefit. This study aimed to develop an interpretable machine‐learning model for stage IB LSCC survival prediction and re‐evaluate postoperative chemotherapy's added value. Methods: A total of 6445 patients with stage IB LSCC diagnosed between 2000 and 2015 were extracted from the SEER database. Patients from 2000 to 2014 ( n = 5740) were split 7:3 into training and internal validation cohorts, while those from 2015 ( n = 705) served as the external validation cohort. Six machine‐learning algorithms (including logistic regression and gradient‐boosting models) were trained to predict 1‐, 3‐, and 5‐year overall survival (OS) with hyperparameter optimization via 10‐fold cross‐validation. SHAP analysis ensured model interpretability, and 1:1 nearest‐neighbor propensity‐score matching evaluated chemotherapy benefit in completely resected patients. Results: The LightGBM model achieved the best discriminative performance (AUC = 0.834, 0.828, 0.800 for 1‐, 3‐, 5‐year OS) with excellent generalizability in external validation. SHAP analysis identified treatment modality as the top survival predictor; both surgery alone and surgery plus chemotherapy improved survival, but no significant OS difference was observed between the two strategies across all timepoints, consistent across subgroups (age, tumor size, etc.). Propensity‐score matching of 565 patients confirmed similar outcomes (median OS: 64 vs. 62 months; HR = 1.01, 95% CI: 0.82–1.20; p = 0.893). Conclusion: This study gives individualized survival estimates for stage IB LSCC, backing a risk‐adapted conservative adjuvant treatment approach. High‐risk subgroups got no extra benefit from postoperative chemotherapy, which may help integrate precision medicine and shared decision‐making in early‐stage LSCC management.
- 7 April 2026
- Published by Wiley in Thoracic Cancer
- Vol. 17 (7) , e70270
Open AccessOptimizing Surgery Strategies in Stage IB Lung Squamous Cell Carcinoma: Insights from Interpretable Machine Learning
Background: Stage IB lung squamous‐cell carcinoma (LSCC) lacks individualized survival prediction tools. There's debate on adjuvant chemotherapy's benefit. This study aimed to develop an interpretable machine‐learning model for stage IB LSCC survival prediction and re‐evaluate postoperative chemotherapy's added value. Methods: A total of 6445 patients with stage IB LSCC diagnosed between 2000 and 2015 were extracted from the SEER database. Patients from 2000 to 2014 ( n = 5740) were split 7:3 into training and internal validation cohorts, while those from 2015 ( n = 705) served as the external validation cohort. Six machine‐learning algorithms (including logistic regression and gradient‐boosting models) were trained to predict 1‐, 3‐, and 5‐year overall survival (OS) with hyperparameter optimization via 10‐fold cross‐validation. SHAP analysis ensured model interpretability, and 1:1 nearest‐neighbor propensity‐score matching evaluated chemotherapy benefit in completely resected patients. Results: The LightGBM model achieved the best discriminative performance (AUC = 0.834, 0.828, 0.800 for 1‐, 3‐, 5‐year OS) with excellent generalizability in external validation. SHAP analysis identified treatment modality as the top survival predictor; both surgery alone and surgery plus chemotherapy improved survival, but no significant OS difference was observed between the two strategies across all timepoints, consistent across subgroups (age, tumor size, etc.). Propensity‐score matching of 565 patients confirmed similar outcomes (median OS: 64 vs. 62 months; HR = 1.01, 95% CI: 0.82–1.20; p = 0.893). Conclusion: This study gives individualized survival estimates for stage IB LSCC, backing a risk‐adapted conservative adjuvant treatment approach. High‐risk subgroups got no extra benefit from postoperative chemotherapy, which may help integrate precision medicine and shared decision‐making in early‐stage LSCC management.
- Open Access
- 1 April 2026
- Published by SAGE Publications in Science Progress
- Vol. 109 (2)
Global, regional and national burden of tracheal, bronchus and lung cancer attributable to occupational carcinogens from 1990 to 2021 and projections to 2050: A finding from the global burden of disease study 2021 and Mendelian randomization
Objective: Occupational exposure to carcinogens significantly contributes to the global burden of tracheal, bronchial, and lung (TBL) cancers. This study aims to quantify the global, regional, and national burden of TBL cancers attributable to occupational carcinogens using Global Burden of Disease (GBD) 2021 data and project trends to 2050. Additionally, we employ Mendelian Randomization (MR) to explore potential causal relationships between modifiable risk factors and TBL cancers. Methods: We extracted mortality and Disability-Adjusted Life Year (DALY) data for TBL cancers caused by occupational carcinogens from the GBD 2021 database. Exponential smoothing and autoregressive integrated moving average (ARIMA) models projected the burden to 2050. Two-sample MR analysis utilized genome-wide association study (GWAS) data, primarily from individuals of European ancestry, to investigate causal links. Results: In 2021, occupational carcinogens caused 285,628 deaths and 6.12 million DALYs globally. While age-standardized mortality and DALY rates declined in some high-income countries, low- and middle-income countries (LMICs) showed rising trends. Projections indicate a potential shift, with some regions plateauing while others face increasing burdens due to persistent exposure. MR analysis confirmed significant causal relationships, identifying higher BMI, smoking, visceral adiposity, and waist circumference as risk factors, while coffee consumption, dried fruit intake, physical activity, and education were protective. Conclusion: Despite progress, the burden of occupational TBL cancers remains substantial, particularly in LMICs. The discordance between declining rates in high-income nations and rising burdens elsewhere highlights the need for targeted interventions and stricter regulations. Integrating genetic evidence supports precision prevention strategies focusing on both occupational safety and modifiable lifestyle factors.
- 1 April 2026
- Published by SAGE Publications in Science Progress
- Vol. 109 (2)
Open AccessGlobal, regional and national burden of tracheal, bronchus and lung cancer attributable to occupational carcinogens from 1990 to 2021 and projections to 2050: A finding from the global burden of disease study 2021 and Mendelian randomization
Objective: Occupational exposure to carcinogens significantly contributes to the global burden of tracheal, bronchial, and lung (TBL) cancers. This study aims to quantify the global, regional, and national burden of TBL cancers attributable to occupational carcinogens using Global Burden of Disease (GBD) 2021 data and project trends to 2050. Additionally, we employ Mendelian Randomization (MR) to explore potential causal relationships between modifiable risk factors and TBL cancers. Methods: We extracted mortality and Disability-Adjusted Life Year (DALY) data for TBL cancers caused by occupational carcinogens from the GBD 2021 database. Exponential smoothing and autoregressive integrated moving average (ARIMA) models projected the burden to 2050. Two-sample MR analysis utilized genome-wide association study (GWAS) data, primarily from individuals of European ancestry, to investigate causal links. Results: In 2021, occupational carcinogens caused 285,628 deaths and 6.12 million DALYs globally. While age-standardized mortality and DALY rates declined in some high-income countries, low- and middle-income countries (LMICs) showed rising trends. Projections indicate a potential shift, with some regions plateauing while others face increasing burdens due to persistent exposure. MR analysis confirmed significant causal relationships, identifying higher BMI, smoking, visceral adiposity, and waist circumference as risk factors, while coffee consumption, dried fruit intake, physical activity, and education were protective. Conclusion: Despite progress, the burden of occupational TBL cancers remains substantial, particularly in LMICs. The discordance between declining rates in high-income nations and rising burdens elsewhere highlights the need for targeted interventions and stricter regulations. Integrating genetic evidence supports precision prevention strategies focusing on both occupational safety and modifiable lifestyle factors.
- Open Access
- 4 March 2021
- Published by Wiley in Thoracic Cancer
- Vol. 12 (7) , 1084-1095
The role of EGFR‐TKIs as adjuvant therapy in EGFR mutation‐positive early‐stage NSCLC: A meta‐analysis
Background: The role of adjuvant epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) is not clear in early‐stage nonsmall‐cell lung cancer (NSCLC) patients. This meta‐analysis aims to compare the efficacy and safety of EGFR‐TKIs as adjuvant therapy with chemotherapy or placebo in NSCLC patients harboring EGFR mutations.Patients and Methods: Pubmed, Embase, and Cochrane databases were searched for randomized controlled trials. The hazard ratio (HR) of disease‐free survival (DFS) and overall survival (OS) as well as the risk ratio (RR) of severe adverse events were merged.Results: Seven articles from five studies from 1843 records, a total of 1227 patients, were included in the analysis. The HR for DFS was 0.38 (95% confidence interval [CI] 0.22–0.63), in favor of EGFR‐TKIs. However, no significant benefit of OS was seen (HR = 0.61, 95% CI 0.31–1.22). Treatment benefit was more pronounced in patients with advanced disease stage and longer duration of medication, EGFR exon 19 deletion mutation, and treatment with third‐generation EGFR‐TKIs. Adjuvant targeted therapy may cause few adverse events compared with chemotherapy (RR = 0.28, 95% CI 0.09–0.94). The possibility of severe adverse events for the first‐generation drugs was significantly lower than for third‐generation drugs.Conclusion: In EGFR mutation‐positive patients with stage IB–IIIA NSCLC, compared with adjuvant chemotherapy or placebo, adjuvant EGFR‐TKIs should effectively improve the patient's DFS, but not effectively improve OS. Disease stage, treatment duration, mutation types, and therapeutic drugs could affect the degree of benefit. Adjuvant EGFR‐TKIs had more favorable tolerability than chemotherapy, especially with the usage of first‐generation drugs.
- 4 March 2021
- Published by Wiley in Thoracic Cancer
- Vol. 12 (7) , 1084-1095
Open AccessThe role of EGFR‐TKIs as adjuvant therapy in EGFR mutation‐positive early‐stage NSCLC: A meta‐analysis
Background: The role of adjuvant epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‐TKIs) is not clear in early‐stage nonsmall‐cell lung cancer (NSCLC) patients. This meta‐analysis aims to compare the efficacy and safety of EGFR‐TKIs as adjuvant therapy with chemotherapy or placebo in NSCLC patients harboring EGFR mutations.Patients and Methods: Pubmed, Embase, and Cochrane databases were searched for randomized controlled trials. The hazard ratio (HR) of disease‐free survival (DFS) and overall survival (OS) as well as the risk ratio (RR) of severe adverse events were merged.Results: Seven articles from five studies from 1843 records, a total of 1227 patients, were included in the analysis. The HR for DFS was 0.38 (95% confidence interval [CI] 0.22–0.63), in favor of EGFR‐TKIs. However, no significant benefit of OS was seen (HR = 0.61, 95% CI 0.31–1.22). Treatment benefit was more pronounced in patients with advanced disease stage and longer duration of medication, EGFR exon 19 deletion mutation, and treatment with third‐generation EGFR‐TKIs. Adjuvant targeted therapy may cause few adverse events compared with chemotherapy (RR = 0.28, 95% CI 0.09–0.94). The possibility of severe adverse events for the first‐generation drugs was significantly lower than for third‐generation drugs.Conclusion: In EGFR mutation‐positive patients with stage IB–IIIA NSCLC, compared with adjuvant chemotherapy or placebo, adjuvant EGFR‐TKIs should effectively improve the patient's DFS, but not effectively improve OS. Disease stage, treatment duration, mutation types, and therapeutic drugs could affect the degree of benefit. Adjuvant EGFR‐TKIs had more favorable tolerability than chemotherapy, especially with the usage of first‐generation drugs.